Absolute Healthcare (Central) Limited

	Page
Company Information	1
Strategic Report	2
Directors' Report	3—4
Independent Auditor's Report	5—8
Profit and Loss Account	9
Statement of Comprehensive Income	10
Balance Sheet	11
Statement of Changes in Equity	12
Statement of Cash Flows	13
Notes to the Statement of Cash Flows	14
Notes to the Financial Statements	15—22

Page 1

Page 2

Strategic Report

For The Year Ended 30 September 2024

Strategic Report

The directors present their strategic report for the year ended 30 September 2024.

Review of the Business

A summary of the results for the year is given on page 8 of the Financial Statements.

The company's principal trade is the operation of a care home. In respect of its trading activities as a care home during the year ended 30 September 2024 fees received decreased by £74,280, an decrease of 2.12% from the previous year.

Wages and salaries costs during the period have significantly increased. This is the main reason that the profit before tax for the year has decreased compared to the previous year. The profit before tax margin for this year is 16.6% compared to 25.6% last year.

The closing balance sheet for the Company remains strong. Current assets and net current assets are down on the previous year as surplus cash has been used to repay a large proportion of the outstanding bank loan. That being said, there are still strong cash levels at the year end date to meet upcoming liabilities.

We believe this strong balance sheet will provide the business with a good platform to move forward and continue to trade as a going concern despite fears of further rising costs and inflation.

The group's key financial and other performance indicators during the year were as follows:

		2024	2023
		£	£
EBITDA	£	729,811	1,094,985

Principal Risks and Uncertainties

High quality care and high quality general health and safety standards need to be maintained to ensure the company mitigates risks and uncertainties and continues to be successful. It is the company' aim to continue to meet and exceed statutory requirements through rigorous monitoring procedures and careful vetting and training of staff.

Continued uncertainty surrounding instability in the UK economy and the ongoing effect of overseas wars on international supply chains is an aspect which is unlikely to have a direct effect on the Company's ability to raise finance.

Despite the significant changes to the care industry since the COVID-19 pandemic, these changes have had a big impact on how the care home operates but little impact on the ability for the Company to continue as a going concern.

Financial Instruments

Objectives and policies

The company's principal financial instruments comprise bank balances, trade creditors and trade debtors. The main purpose of these instruments is to raise funds for, and to finance, the Company's operations.

Price risk, credit risk, liquidity risk and cash flow risk

Due to the nature of the financial instruments used by the company there is no exposure to price risk. The Company's approach to managing other risks applicable to the financial instruments concerned is shown below.

In respect of bank balances and bank loans the liquidity risk is managed by maintaining positive bank balances and ensuring loan repayments are met and covenants are not breached.

Trade debtors are managed in respect of credit and cash flow risk by policies concerning each resident in the Company's care and each debt owed and the regular monitoring of amounts outstanding for both time and credit allowed.

Trade creditors liquidity risk is managed by ensuring sufficient funds are available to meet amounts due.

On behalf of the board

Dr J S Badial

Director

29 September 2025

Page 2

Page 3

Absolute Healthcare (Central) Limited

Company No. 07690371

Directors' Report For The Year Ended 30 September 2024

Directors' Report

The directors present their report and the financial statements for the year ended 30 September 2024.

Principal Activity

The company's principal activity continues to be that of the provision of health care for the elderly.

Dividends

The value of dividends paid amounted to £120,000 .

The directors recommended a final dividend of £NIL .

Directors

The directors who held office during the year were as follows:

Dr M S Pawar	Resigned	01/12/2023
Dr J S Badial

Matters covered in the Strategic Report

Disclosures required under s416(4) of the Companies Act 2006 are commented upon in the Strategic Report as the directors consider them to be of strategic importance to the business.

Statement of Directors' Responsibilities

The directors are responsible for preparing the Strategic Report, the Directors' Report and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards, comprising FRS102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland', and applicable law). Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing the financial statements the directors are required to:

select suitable accounting policies and then apply them consistently;
make judgments and accounting estimates that are reasonable and prudent;
state whether applicable United Kingdom Accounting Standards, comprising FRS102, have been followed subject to any material departures disclosed and explained in the financial statements;
prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The directors are responsible for the maintenance and integrity of the corporate and financial information included on the company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

Statement of Disclosure of Information to Auditors

In the case of each director in office at the date the Directors' Report is approved:

so far as the director is aware, there is no relevant audit information of which the company's auditors are unaware; and
they have taken all the steps that they ought to have taken as directors in order to make themselves aware of any relevant audit information and to establish that the company's auditors are aware of that information.

Page 3

Page 4

Absolute Healthcare (Central) Limited

Directors' Report (continued)

For The Year Ended 30 September 2024

Independent Auditors

The auditors, Nuvo Audit Limited, have indicated their willingness to continue in office and a resolution concerning their re-appointment will be proposed at the Annual General Meeting.

On behalf of the board

Dr J S Badial

Director

29 September 2025

Page 4

Page 5

Independent Auditor's Report

to the Members of

Absolute Healthcare (Central) Limited

Independent Auditor's Report

Qualified opinion

We have audited the financial statements of Absolute Healthcare (Central) Limited for the year ended 30 September 2024 which comprise the Profit and Loss Account, Statement of Comprehensive Income, Balance Sheet, Statement of Changes of Equity, Cash Flow Statement and the related notes, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice), including FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland".

Basis for Qualified Opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

During our audit, we were unable to obtain sufficient appropriate audit evidence regarding the closing balance sheet as at 30 September 2023 as the comparative financial statements were not audited. As a result, we cannot express an opinion on the accuracy of the opening balance sheet for this financial period although we are not aware of any material misstatements that would impact the financial statements for the year ending 30 September 2024.

Conclusions Relating to Going Concern

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the entity's ability to continue as a going concern for a period of at least 12 months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Other Information

The other information comprises the information included in the annual report, other than the financial statements and our auditor's report thereon. The directors are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Opinions on Other Matters Prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

the information given in the Strategic Report and Directors' Report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
the Strategic Report and Directors' Report have been prepared in accordance with applicable legal requirements.

Page 5

Page 6

Independent Auditor's Report (continued)

to the Members of

Absolute Healthcare (Central) Limited

Matters on Which We Are Required to Report by Exception

In the light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the Strategic Report or the Directors' Report.

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:

adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
the financial statements are not in agreement with the accounting records or returns; or
certain disclosures of directors' remuneration specified by law are not made; or
we have not received all the information and explanations we require for our audit.

In respect solely of the limitation of our work relating to the opening balance sheet as at 30 September 2023, described above:

we have not obtained all the information and explanations that we considered necessary for the purpose of our audit;
we were unable to determine whether adequate accounting records had been maintained.

Responsibilities of Directors

As explained more fully in the Directors' Responsibilities Statement set out on page 3—4, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.

Page 6

Page 7

Independent Auditor's Report (continued)

to the Members of

Absolute Healthcare (Central) Limited

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

Based on our knowledge and understanding of the Company and industry, we identified that the key risk of fraud or non-compliance with laws and regulations related to:

Management bias in respect of accounting estimates and judgements made.

Management override of control.

Posting of unusual journals or transactions.

Non-compliance with CQC regulations.

We focused on those areas that could give rise to a material misstatement in the Company financial statements. Our procedures included but were not limited to:

Enquiring of management and those charged with governance around actual and potential litigation and claims, including instances of non-compliance with laws and regulations and fraud.

Reviewing legal expenditure in the year to identify instances of non-compliance with laws and regulations and fraud.

Reviewing financial statement disclosures and testing to supporting documentation to assess compliance with applicable laws and regulations.

Performing audit work over the risk of management override of controls including testing of journal entries and other adjustments for appropriateness, evaluating the business rationale of significant transactions outside the normal course of business.

Performing analytical procedures to identify any unusual or unexpected relationships that may indicate an increased risk of material misstatement as a result of fraud, or management override.

Assessing accounting estimates which have a material impact of the year end accounts, to determine if there is indication of management bias.

We also communicated relevant identified laws and regulations and potential fraud risks to all engagement team members and remained alert to any indications of fraud or non-compliance with laws and regulations throughout the audit.

It is the primary responsibility of management, with the oversight of those charged with governance, to ensure that the entity’s operations are conducted in accordance with the provisions of laws and regulations and for the prevention and detection of fraud.

Our audit did not identify any key audit matters relating to the detection of irregularities including fraud. However, despite the audit being planned and conducted in accordance with ISAs (UK) there remains an unavoidable risk that material misstatements in the financial statements may not be detected owing to inherent limitations of the audit, and that by their very nature, any such instances of fraud or irregularity likely involve collusion, forgery, intentional misrepresentations, or the override of internal controls.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.

Use Of Our Report

This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters that we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.

Page 7

Page 8

Independent Auditor's Report (continued)

to the Members of

Absolute Healthcare (Central) Limited

Mr Daniel Johnson FCCA (Senior Statutory Auditor)

for and on behalf of Nuvo Audit Limited , Statutory Auditor

29 September 2025

Nuvo Audit Limited

First Floor, Sterling House

Outrams Wharf

Little Eaton

Derby

DE21 5EL

Page 8

Page 9

Absolute Healthcare (Central) Limited

Profit and Loss Account

For The Year Ended 30 September 2024

Profit and Loss Account

		2024	2023
	Notes	£	£
TURNOVER	3	3,432,807	3,507,087
Cost of sales		(2,134,883 )	(1,976,703 )

GROSS PROFIT		1,297,924	1,530,384

Administrative expenses		(606,412 )	(472,451 )

OPERATING PROFIT	4	691,512	1,057,933
Other interest receivable and similar income	9	15,360	8,429
Interest payable and similar charges	10	(136,477 )	(167,361 )

PROFIT BEFORE TAXATION		570,395	899,001
Tax on Profit	11	(148,556 )	(220,196 )

PROFIT AFTER TAXATION BEING PROFIT FOR THE FINANCIAL YEAR		421,839	678,805

The notes on pages 14 to 22 form part of these financial statements.

Page 9

Page 10

Absolute Healthcare (Central) Limited

Statement of Comprehensive Income

For The Year Ended 30 September 2024

Statement of Comprehensive Income

	2024	2023
	£	£
PROFIT FOR THE FINANCIAL YEAR	421,839	678,805
OTHER COMPREHENSIVE INCOME FOR THE YEAR	-	-

TOTAL COMPREHENSIVE INCOME FOR THE YEAR	421,839	678,805

Page 10

Page 11

Absolute Healthcare (Central) Limited

Balance Sheet

As At 30 September 2024

Balance Sheet

Registered number: 07690371

		2024		2023
	Notes	£	£	£	£
FIXED ASSETS
Intangible Assets	12		2		2
Tangible Assets	13		1,618,211		1,616,561

			1,618,213		1,616,563
CURRENT ASSETS
Stocks	14	5,000		2,000
Debtors	15	2,732,685		2,558,108
Cash at bank and in hand		659,970		1,896,421

		3,397,655		4,456,529
Creditors: Amounts Falling Due Within One Year	16	(659,308 )		(915,003 )

NET CURRENT ASSETS (LIABILITIES)			2,738,347		3,541,526

TOTAL ASSETS LESS CURRENT LIABILITIES			4,356,560		5,158,089

Creditors: Amounts Falling Due After More Than One Year	17		(916,478 )		(2,025,702 )

PROVISIONS FOR LIABILITIES
Deferred Taxation	19		(35,764 )		(29,908 )

NET ASSETS			3,404,318		3,102,479

CAPITAL AND RESERVES
Called up share capital	21		2		2
Profit and Loss Account			3,404,316		3,102,477

SHAREHOLDERS' FUNDS			3,404,318		3,102,479

On behalf of the board

Dr J S Badial

Director

29 September 2025

The notes on pages 14 to 22 form part of these financial statements.

Page 11

Page 12

Absolute Healthcare (Central) Limited

Statement of Changes in Equity

For The Year Ended 30 September 2024

Statement of Changes in Equity

	Share Capital	Profit and Loss Account	Total
	£	£	£
As at 1 October 2022	2	2,493,672	2,493,674
Profit for the year and total comprehensive income	-	678,805	678,805

Dividends paid	-	(70,000)	(70,000)

As at 30 September 2023 and 1 October 2023	2	3,102,477	3,102,479


Profit for the year and total comprehensive income	-	421,839	421,839

Dividends paid	-	(120,000)	(120,000)

As at 30 September 2024	2	3,404,316	3,404,318

Page 12

Page 13

Absolute Healthcare (Central) Limited

Statement of Cash Flows

For The Year Ended 30 September 2024

Statement of Cash Flows

		2024	2023
	Notes	£	£
Cash flows from operating activities
Net cash generated from operations	1	546,767	1,284,512
Tax paid		(201,215 )	(179,012 )

Net cash generated from operating activities		345,552	1,105,500

Cash flows from investing activities
Purchase of tangible assets		(39,949 )	(20,421 )
Interest received		15,360	8,429
Receivables from associated companies		(49,577)	-

Net cash used in investing activities		(74,166 )	(11,992 )

Cash flows from financing activities
Equity dividends paid		(120,000 )	(70,000 )
Repayment of bank borrowings		(1,305,214 )	(122,374 )
Amount introduced by directors		141,659	88,325
Amount withdrawn by directors		(87,805)	(155,999)
Interest paid		(136,477)	(167,361)

Net cash used in financing activities		(1,507,837 )	(427,409 )



(Decrease)/increase in cash and cash equivalents		(1,236,451 )	666,099
Cash and cash equivalents at beginning of year	2	1,896,421	1,230,322

Cash and cash equivalents at end of year	2	659,970	1,896,421

Page 13

Page 14

Absolute Healthcare (Central) Limited

Notes to the Statement of Cash Flows

For The Year Ended 30 September 2024

Notes to the Statement of Cash Flows

1. Reconciliation of profit for the financial year to cash generated from operations

	2024	2023
	£	£
Profit for the financial year	421,839	678,805
Adjustments for:
Tax on profit	148,556	220,196
Interest expense	136,477	167,361
Interest income	(15,360 )	(8,429 )
Depreciation of tangible assets	38,299	37,052
Movements in working capital:
Increase in stocks	(3,000 )	-
(Increase)/decrease in trade and other debtors	(125,000 )	85,216
(Decrease)/increase in trade and other creditors	(55,044 )	104,311

Net cash generated from operations	546,767	1,284,512

2. Cash and cash equivalents

Cash and cash equivalents, as stated in the Statement of Cash Flows, relates to the following items in the Balance Sheet:

	2024	2023
	£	£
Cash at bank and in hand	659,970	1,896,421

3. Analysis of changes in net debt

	As at 1 October 2023	Cash flows	As at 30 September 2024
	£	£	£
Cash at bank and in hand	1,896,421	(1,236,451)	659,970
Debts falling due within one year	(334,938 )	195,990	(138,948 )
Debts falling due after more than one year	(2,025,702)	1,109,224	(916,478)

	(464,219)	68,763	(395,456)

Page 14

Page 15

Absolute Healthcare (Central) Limited

Notes to the Financial Statements

For The Year Ended 30 September 2024

Notes to the Financial Statements

1. General Information

Absolute Healthcare (Central) Limited is a private company, limited by shares, incorporated in England & Wales, registered number 07690371 . The registered office is The Willows, Ransom Wood Business Park, Southwell Road West, Rainworth, Mansfield, Nottinghamshire, NG21 0HJ.

2. Accounting Policies

2.1. Basis of Preparation of Financial Statements

The financial statements have been prepared under the historical cost convention and in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland'' and the Companies Act 2006.

The Company's financial statements are presented in sterling and all values are rounded to the nearest pound.

2.2. Going Concern Disclosure

The directors have not identified any material uncertainties related to events or conditions that may cast significant doubt about the company's ability to continue as a going concern.

2.3. Significant judgements and estimations

In the application of the company's accounting policies, management is required to make judgements, estimates and assumptions about the carrying value of assets and liabilities that are not readily apparent from other sources. The estimates and underlying assumptions are based on historical experience and are reviewed on an ongoing basis.

Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods.

The key sources of estimation uncertainty that have an impact on the amounts recognised in the financial statements are:

Provision for bad and doubtful debts

The company assesses the recoverability of trade receivables at each reporting date and recognises a provision for bad debts where appropriate. Key areas of judgement include:

The estimation of bad debt provisions involves significant judgement and is subject to change based on actual credit losses experienced.

2.4. Turnover

Turnover is measured at the fair value of the consideration received or receivable for the provision of services in the ordinary course of the Company's activities. Turnover is shown net of sales/value added taxes, rebates and discounts. Turnover is recognised on a daily basis when the service and care have been received by the resident. These services are invoiced on a periodic basis. Turnover received in advance is treated as deferred income and recognised as income in future trading periods.

2.5. Intangible Fixed Assets and Amortisation - Goodwill

Goodwill arising on the acquisition of an entity represents the excess of the cost of acquisition over the company’s interest in the net fair value of the identifiable assets, liabilities and contingent liabilities of the entity recognised at the date of acquisition. Goodwill is initially recognised as an asset at cost and is subsequently measured at cost less accumulated amortisation and accumulated impairment losses. Goodwill is held in the currency of the acquired entity and revalued to the closing rate at each reporting period date. Goodwill is amortised over its useful life, which shall not exceed ten years if a reliable estimate of the useful life cannot be made.

2.6. Tangible Fixed Assets and Depreciation

Tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. Depreciation is provided at rates calculated to write off the cost of the fixed assets, less their estimated residual value, over their expected useful lives on the following bases:

Freehold	1% straight line basis
Plant & Machinery	20% reducing balance basis
Motor Vehicles	20% reducing balance basis
Fixtures & Fittings	15% reducing balance basis

The Freehold category above reflects the depreciation method of the Freehold Property held within that category. Freehold land is not depreciated.

Page 15

Page 16

Absolute Healthcare (Central) Limited

Notes to the Financial Statements (continued)

For The Year Ended 30 September 2024

2.7. Stocks and Work in Progress

Stocks and work in progress are valued at the lower of cost and net realisable value after making due allowance for obsolete and slow-moving stocks.

Cost is determined using the first-in, first-out method. Cost includes all direct costs and an appropriate proportion of fixed and variable overheads.

Work in progress is reflected in the accounts on a contract by contract basis by recording turnover and related costs as contract activity progresses.

At the end of each reporting period stocks are assessed for impairment. If an item of stock is impaired, the identified stock is reduced to its selling price less costs to complete and sell and an impairment charge is recognised in the profit and loss account. Where a reversal of the impairment is required the impairment charge is reversed, up to the original impairment loss, and is recognised as a credit in the profit and loss account.

2.8. Cash and Cash Equivalents

Cash and cash equivalents are basic financial assets and include cash in hand and deposits held at call with banks, other short-term highly liquid investments that mature in no more than three months from the date of acquisition and are readily convertible to a known amount of cash with insignificant risk of change in value, and bank overdrafts.

2.9. Financial Instruments

The company has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Other financial assets

Other financial assets, including investments in equity instruments which are not subsidiaries, associates or joint ventures, are initially measured at fair value, which is normally the transaction price. Such assets are subsequently carried at fair value and the changes in fair value are recognised in profit or loss, except that investments in equity instruments that are not publicly traded and whose fair values cannot be measured reliably are measured at cost less impairment.

2.10. Taxation

Income tax expense represents the sum of the tax currently payable and deferred tax.

The tax currently payable is based on taxable profit for the year. Taxable profit differs from profit as reported in the statement of comprehensive income because of items of income or expense that are taxable or deductible in other years and items that are never taxable or deductible. The company's liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period.

Deferred tax is recognised on timing differences between the carrying amounts of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit. Deferred tax liabilities are generally recognised for all taxable timing differences. Deferred tax assets are generally recognised for all deductible temporary differences to the extent that it is probable that taxable profits will be available against which those deductible timing differences can be utilised. The carrying amount of deferred tax assets is reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the period in which the liability is settled or the asset realised, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period. Deferred tax liabilities are presented within provisions for liabilities and deferred tax assets within debtors. The measurement of deferred tax liabilities and assets reflect the tax consequences that would follow from the manner in which the Company expects, at the end of the reporting period, to recover or settle the carrying amount of its assets and liabilities.

Current and deferred tax are recognised in profit or loss for the year, except when they relate to items that are recognised in other comprehensive income or directly in equity, in which case current and deferred tax are recognised in other comprehensive income or directly in equity respectively.

Page 16

Page 17

Absolute Healthcare (Central) Limited

Notes to the Financial Statements (continued)

For The Year Ended 30 September 2024

2.11. Pensions

The company operates a defined pension contribution scheme. Contributions are charged to the profit and loss account as they become payable in accordance with the rules of the scheme.

2.12. Share capital

Ordinary shares are classified as equity. Equity instruments are measured at fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

3. Turnover

Analysis of turnover by geographical market is as follows:

	2024	2023
	£	£
United Kingdom	3,432,807	3,507,087

	3,432,807	3,507,087

4. Operating Profit

The operating profit is stated after charging:

	2024	2023
	£	£
Depreciation of tangible fixed assets	38,299	37,052

5. Auditor's Remuneration

Remuneration received by the company's auditors and their associates during the year was as follows:

	2024	2023
	£	£
Audit Services
Audit of the company's financial statements	12,000	-

6. Staff Costs

Staff costs, including directors' remuneration, were as follows:

	2024	2023
	£	£
Wages and salaries	1,801,542	1,555,066
Social security costs	137,297	99,595
Other pension costs	120,736	23,084

	2,059,575	1,677,745

7. Average Number of Employees

Average number of employees, including directors, during the year was: 109 (2023: 99)

Page 17

Page 18

Absolute Healthcare (Central) Limited

Notes to the Financial Statements (continued)

For The Year Ended 30 September 2024

8. Directors' remuneration

	2024	2023
	£	£
Emoluments	12,570	12,237
Company contributions to money purchase pension schemes	90,000	-

	102,570	12,237

The number of directors to whom retirement benefits were accruing was as follows:

	2024		2023
Money purchase pension schemes	1		-

9. Interest Receivable and Similar Income

	2024	2023
	£	£
Bank interest receivable	15,360	8,429

10. Interest Payable and Similar Charges

	2024	2023
	£	£
Bank loans and overdrafts	136,477	167,361

11. Tax on Profit

	2024	2023
The tax charge on the profit for the year was as follows:
	£	£
Current tax
UK Corporation Tax	142,186	201,215
Prior period adjustment	514	-

	142,700	201,215
Deferred Tax
Changes in tax rates	5,443	-
Origination and reversal of timing differences	413	18,981

	5,856	18,981


Total tax charge for the period	148,556	220,196


The actual charge for the year can be reconciled to the expected charge for the year based on the profit and the standard rate of corporation tax as follows:
	2024	2023
	£	£
Profit before tax	570,395	899,001

Tax on profit at 25% (UK standard rate)	142,599	197,780

...CONTINUED

Page 18

Page 19

Absolute Healthcare (Central) Limited

Notes to the Financial Statements (continued)

For The Year Ended 30 September 2024

Expenses not deductible for tax purposes	-	22,416
Prior period adjustment	514	-
Deferred tax relating to changes in tax rates or laws	5,443	-

Total tax charge for the period	148,556	220,196

12. Intangible Assets

	Goodwill
	£
Cost
As at 1 October 2023	2

As at 30 September 2024	2

Net Book Value
As at 30 September 2024	2

As at 1 October 2023	2

13. Tangible Assets

	Land & Property
	Freehold	Plant & Machinery	Motor Vehicles	Fixtures & Fittings	Total
	£	£	£	£	£
Cost
As at 1 October 2023	1,562,460	57,458	1,119	275,252	1,896,289
Additions	7,742	16,487	-	15,720	39,949

As at 30 September 2024	1,570,202	73,945	1,119	290,972	1,936,238

Depreciation
As at 1 October 2023	81,846	35,543	308	162,031	279,728
Provided during the period	13,201	6,456	162	18,480	38,299

As at 30 September 2024	95,047	41,999	470	180,511	318,027

Net Book Value
As at 30 September 2024	1,475,155	31,946	649	110,461	1,618,211

As at 1 October 2023	1,480,614	21,915	811	113,221	1,616,561

14. Stocks

	2024	2023
	£	£
Raw materials and consumables	5,000	2,000

Page 19

Page 20

Absolute Healthcare (Central) Limited

Notes to the Financial Statements (continued)

For The Year Ended 30 September 2024

15. Debtors

	2024	2023
	£	£
Due within one year
Trade debtors	192,351	138,111
Prepayments and accrued income	15,290	19,953
Amounts owed by other participating interests	2,525,044	2,400,044

	2,732,685	2,558,108

16. Creditors: Amounts Falling Due Within One Year

	2024	2023
	£	£
Trade creditors	67,132	44,324
Bank loans and overdrafts	138,948	334,938
Corporation tax	142,186	200,701
Other taxes and social security	56,565	55,113
Other creditors	132,802	204,222
Accruals and deferred income	121,675	75,705

	659,308	915,003

17. Creditors: Amounts Falling Due After More Than One Year

	2024	2023
	£	£
Bank loans	916,478	2,025,702

A fixed and floating charge was created on 6 May 2022 in favour of Clydesdale Bank PLC against all the property or undertaking of the company.

	2024		2023
	£		£
Bank loans and overdrafts	1,055,426		2,360,640

18. Loans

An analysis of the maturity of loans is given below:

	2024	2023
	£	£
Amounts falling due within one year or on demand:
Bank loans	138,948	334,938

	2024	2023
	£	£
Amounts falling due between one and five years:
Bank loans	916,478	2,025,702

Bank loan is denominated in sterling with a nominal interest rate of 7.35%. The carrying amount at the year end is £1,055,426.

The loan is to be repaid in its entirety by May 2027.

Page 20

Page 21

Absolute Healthcare (Central) Limited

Notes to the Financial Statements (continued)

For The Year Ended 30 September 2024

19. Deferred Taxation

The provision for deferred tax is made up as follows:

	2024	2023
	£	£
Other timing differences	35,764	29,908

20. Provisions for Liabilities


	Deferred Tax	Total
	£	£
As at 1 October 2023	29,908	29,908
Changes in tax rates	5,443	5,443
Origination and reversal of timing differences	413	413

Balance at 30 September 2024	35,764	35,764

21. Share Capital

	2024	2023
Allotted, called up and fully paid	£	£
2 Ordinary Shares of £ 1.000 each	2	2

22. Financial Instruments

The company has the following financial instruments:

	2024	2023
	£	£
Financial assets
Financial assets that are debt Instruments measured at amortised cost	3,377,365	4,434,576

Financial liabilities
Financial liabilities measured at amortised cost	1,341,929	2,726,627

Financial assests measured at amortised cost included trade and other debtors and cash and cash equivalents.

Financial liabilities measured at amortised cost include trade and other creditors, bank loans, other taxation and social security and accruals.

23. Pension Commitments

The company operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the company in an independently administered fund.

During the year the charge to profit or loss in respect of defined contribution schemes was £120,736 (2023: £23,084).

At the balance sheet date contributions of £5,790 (2023: £5,237) were due to the fund and are included in creditors.

Page 21

Page 22

Absolute Healthcare (Central) Limited

Notes to the Financial Statements (continued)

For The Year Ended 30 September 2024

24. Directors Advances, Credits and Guarantees

Included within Debtors are the following loans to directors:

	As at 1 October 2023	Amounts advanced	Amounts repaid	Amounts written off	As at 30 September 2024
	£	£	£	£	£
Dr Jagveer Badial	-	82,650	(82,650 )	-	-

Amounts advanced are interest free and repayable on demand.

25. Dividends

	2024	2023
	£	£
On equity shares:
Interim dividend paid	120,000	70,000

26. Related Party Disclosures

During the year, the Company transferred loan balances of £125,000 (2023: £1,599,985) to companies under common control.

Included within debtors at 30 September 2024 is a loan balance of £2,525,044 (2023: £2,400,044) which is due from companies under common control. All amounts due are interest free and repayable on demand.

27. Controlling Parties

The company's ultimate controlling party is Dr J S Badial .

Page 22

Director	Dr J S Badial

Company Number	07690371

Registered Office	The Willows, Ransom Wood Business Park
	Southwell Road West
	Rainworth, Mansfield
	Nottinghamshire
	NG21 0HJ

Business	The Gables
	1595 Wolverhampton Road
	Oldbury
	West Midlands
	B69 2BJ

Auditors	Nuvo Audit Limited
	First Floor, Sterling House
	Outrams Wharf
	Little Eaton
	Derby
	DE21 5EL